Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs CD45 antigen inhibitors; LMP1-LMP2-specific T lymphocyte therapy
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Acronyms DELLA
- 16 Apr 2012 Biomarkers information updated
- 13 Apr 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.